Prelude’s lead product candidates, PRT543 and PRT811, are designed to be oral, potent, and selective PRMT5 inhibitors.

PRT811, Prelude’s second clinical product candidate, is an oral PRMT5 inhibitor under development for patients with PRMT5-dependent cancers, including central nervous system (CNS) tumors such as glioblastoma multiforme (GBM) and primary CNS lymphoma. PRT811 is designed to have high potency and selectivity and optimized brain exposure.

PRT811 is being studied in a Phase 1 clinical trial in solid tumors, including GBM and primary central nervous system lymphomas (PCNSL).

811 Graphic